Abstract
Patients with psychotic disorders have increased rates of medical comorbidities. In this cross-sectional study, we investigated the relationship between antipsychotics and medical comorbidities among patients with psychotic disorders in an urban psychiatry clinic in Atlanta, Georgia (n = 860). Each antipsychotic group was compared to a group of patients from the same sample who were not on any antipsychotic, and logistic regression models were constructed for each comorbidity. Ziprasidone was associated with diabetes (aOR 2.56, 95% CI 1.03–6.38) and obesity (aOR 3.19, 95% CI 1.37–7.41). Aripiprazole was associated with obesity (aOR 2.39, 95% CI 1.27–4.51). Clozapine was associated with GERD (aOR 3.59, 95% CI 1.11–11.61), movement disorders (aOR 4.44, 95% CI 1.02–19.32), and arrythmias (4.89, 95% CI 1.44–16.64). Two antipsychotics that are considered weight neutral, ziprasidone and aripiprazole, were associated with cardiometabolic comorbidities. This study suggests that research is warranted to study the association between antipsychotics, medical comorbidity, and psychotic symptom burden.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cini, E., Rossi, M., McCormick, P. J., Corsini, G. U., Maggio, R., & Scarselli, M. (2018). Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacology & Therapeutics, 192, 20–41. https://doi.org/10.1016/j.pharmthera.2018.06.012
Barton, B. B., Segger, F., Fischer, K., Obermeier, M., & Musil, R. (2020). Update on weight-gain caused by antipsychotics: A systematic review and meta-analysis. Expert Opinion on Drug Safety, 19(3), 295–314. https://doi.org/10.1080/14740338.2020.1713091
Bellon, A., & Nguyen, K. (2021). Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: A controversial but promising approach. World Journal of Psychiatry, 11(7), 316–324. https://doi.org/10.5498/wjp.v11.i7.316
Bloechliger, M., Ruegg, S., Jick, S. S., Meier, C. R., & Bodmer, M. (2015). Antipsychotic drug use and the risk of seizures: Follow-up study with a nested case-control analysis. CNS Drugs, 29(7), 591–603. https://doi.org/10.1007/s40263-015-0262-y
Boden, R., Edman, G., Reutfors, J., Ostenson, C. G., & Osby, U. (2013). A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatric Disease and Treatment, 9, 371–377. https://doi.org/10.2147/NDT.S40554
Bresee, L. C., Majumdar, S. R., Patten, S. B., & Johnson, J. A. (2010). Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophrenia Research, 117(1), 75–82. https://doi.org/10.1016/j.schres.2009.12.016
Carney, C. P., Jones, L., & Woolson, R. F. (2006). Medical comorbidity in women and men with schizophrenia: A population-based controlled study. Journal of General Internal Medicine, 21(11), 1133–1137. https://doi.org/10.1111/j.1525-1497.2006.00563.x
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020). Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs, 80(17), 1763–1781. https://doi.org/10.1007/s40265-020-01393-x
Chouinard, V. A., Henderson, D. C., Dalla Man, C., Valeri, L., Gray, B. E., Ryan, K. P., Cypess, A. M., Cobelli, C., Cohen, B. M., & Öngür, D. (2019). Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis. Molecular Psychiatry, 24(10), 1513–1522. https://doi.org/10.1038/s41380-018-0045-1
Citrome, L., Collins, J. M., Nordstrom, B. L., Rosen, E. J., Baker, R., Nadkarni, A., & Kalsekar, I. (2013). Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. The Journal of Clinical Psychiatry, 74(12), 1199–1206. https://doi.org/10.4088/JCP.13m08642
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14(2), 119–136. https://doi.org/10.1002/wps.20204
Correll, C. U., Solmi, M., Veronese, N., Bortolato, B., Rosson, S., Santonastaso, P., Thapa-Chhetri, N., Fornaro, M., Gallicchio, D., Collantoni, E., Pigato, G., Favaro, A., Monaco, F., Kohler, C., Vancampfort, D., Ward, P. B., Gaughran, F., Carvalho, A. F., & Stubbs, B. (2017). Prevalence, incidence sand mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry, 16(2), 163–180. https://doi.org/10.1002/wps.20420
Cotes, R. O., Goldsmith, D. R., Kopelovich, S. L., Lally, C. A., & Druss, B. G. (2018). Characteristics of medicaid recipients receiving persistent antipsychotic polypharmacy. Community Mental Health Journal, 54(6), 699–706. https://doi.org/10.1007/s10597-017-0183-y
Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatric Services, 49(2), 196–201. https://doi.org/10.1176/ps.49.2.196
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., & Lieberman, J. A. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research, 105(1–3), 175–187. https://doi.org/10.1016/j.schres.2008.07.006
De Fazio, P., Gaetano, R., Caroleo, M., Cerminara, G., Maida, F., Bruno, A., Muscatello, M. R., Moreno, M. J., Russo, E., & Segura-García, C. (2015). Rare and very rare adverse effects of clozapine. Neuropsychiatric Disease and Treatment, 11, 1995–2003. https://doi.org/10.2147/NDT.S83989
de Silva, V. A., Suraweera, C., Ratnatunga, S. S., Dayabandara, M., Wanniarachchi, N., & Hanwella, R. (2016). Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry, 16(1), 341. https://doi.org/10.1186/s12888-016-1049-5
Dreifuss, F. E., & Langer, D. H. (1988). Side effects of valproate. The American Journal of Medicine, 84(1A), 34–41. https://doi.org/10.1016/0002-9343(88)90055-1
Druss, B. G., Bradford, W. D., Rosenheck, R. A., Radford, M. J., & Krumholz, H. M. (2001). Quality of medical care and excess mortality in older patients with mental disorders. Archives of General Psychiatry, 58(6), 565–572. https://doi.org/10.1001/archpsyc.58.6.565
Firth, D. (1993). Bias reduction of maxiumum likelihood esimates. Biometrika, 80(1), 27–38.
Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., Miller, A. H., Mantovani, A., Weyand, C. M., Barzilai, N., Goronzy, J. J., Rando, T. A., Effros, R. B., Lucia, A., Kleinstreuer, N., & Slavich, G. M. (2019). Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 25(12), 1822–1832. https://doi.org/10.1038/s41591-019-0675-0
Garcia, S., Martinez-Cengotitabengoa, M., Lopez-Zurbano, S., Zorrilla, I., Lopez, P., Vieta, E., & Gonzalez-Pinto, A. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. Journal of Clinical Psychopharmacology, 36(4), 355–371. https://doi.org/10.1097/JCP.0000000000000523
Goff, D. C., Cather, C., Evins, A. E., Henderson, D. C., Freudenreich, O., Copeland, P. M., Bierer, M., Duckworth, K., & Sacks, F. M. (2005). Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists. The Journal of Clinical Psychiatry, 66(2), 183–194. https://doi.org/10.4088/jcp.v66n0205
Graham, G. (2015). Disparities in cardiovascular disease risk in the United States. Current Cardiology Reviews, 11(3), 238–245. https://doi.org/10.2174/1573403x11666141122220003
Ingman, K., Honkanen, A., Hyytia, P., Huttunen, M. O., & Korpi, E. R. (2003). Risperidone reduces limited access alcohol drinking in alcohol-preferring rats. European Journal of Pharmacology, 468(2), 121–127. https://doi.org/10.1016/s0014-2999(03)01669-8
Jones, D. R., Macias, C., Barreira, P. J., Fisher, W. H., Hargreaves, W. A., & Harding, C. M. (2004). Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services, 55(11), 1250–1257. https://doi.org/10.1176/appi.ps.55.11.1250
Kagal, U. A., Torgal, S. S., Patil, N. M., & Malleshappa, A. (2012). Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents–a cross-sectional study. Journal of Pharmacy Practice, 25(3), 368–373. https://doi.org/10.1177/0897190012442220
Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019). Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. European Neuropsychopharmacology, 29(1), 32–45. https://doi.org/10.1016/j.euroneuro.2018.11.1105
Kumari, V., & Postma, P. (2005). Nicotine use in schizophrenia: The self medication hypotheses. Neuroscience and Biobehavioral Reviews, 29(6), 1021–1034. https://doi.org/10.1016/j.neubiorev.2005.02.006
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. The Journal of Clinical Psychiatry, 63(10), 892–909. https://doi.org/10.4088/jcp.v63n1007
Laker, M. K., & Cookson, J. C. (1997). Reflux oesophagitis and clozapine. International Clinical Psychopharmacology, 12(1), 37–39. https://doi.org/10.1097/00004850-199701000-00005
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007). Physical illness and schizophrenia: A review of the literature. Acta Psychiatrica Scandinavica, 116(5), 317–333. https://doi.org/10.1111/j.1600-0447.2007.01095.x
Lieberman, J. A., & Safferman, A. Z. (1992). Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatric Quarterly, 63(1), 51–70. https://doi.org/10.1007/BF01064682
Lord, O., Malone, D., & Mitchell, A. J. (2010). Receipt of preventive medical care and medical screening for patients with mental illness: A comparative analysis. General Hospital Psychiatry, 32(5), 519–543. https://doi.org/10.1016/j.genhosppsych.2010.04.004
Lu, M. L., Chen, T. T., Kuo, P. H., Hsu, C. C., & Chen, C. H. (2018). Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study. Schizophrenia Research, 193, 126–133. https://doi.org/10.1016/j.schres.2017.06.030
Lyon, E. R. (1999). A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatric Services, 50(10), 1346–1350. https://doi.org/10.1176/ps.50.10.1346
Martino, D., Karnik, V., Osland, S., Barnes, T. R. E., & Pringsheim, T. M. (2018). Movement disorders associated with antipsychotic medication in people with schizophrenia: An overview of cochrane reviews and meta-analysis. The Canadian Journal of Psychiatry, 63(11), 730–739. https://doi.org/10.1177/0706743718777392
McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012). Lithium toxicity profile: A systematic review and meta-analysis. The Lancet, 379(9817), 721–728. https://doi.org/10.1016/S0140-6736(11)61516-X
Miller, D. D. (2000). Review and management of clozapine side effects. The Journal of Clinical Psychiatry, 61(Suppl 8), 14–17.
Mitchell, A. J., Lord, O., & Malone, D. (2012). Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: Meta-analysis. The British Journal of Psychiatry, 201(6), 435–443. https://doi.org/10.1192/bjp.bp.111.094532
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–a systematic review and meta-analysis. Schizophrenia Bulletin, 39(2), 306–318. https://doi.org/10.1093/schbul/sbr148
Newcomer, J. W., Campos, J. A., Marcus, R. N., Breder, C., Berman, R. M., Kerselaers, W., L’italien, G. J., Nys, M., Carson, W. H., & McQuade, R. D. (2008). A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. The Journal of Clinical Psychiatry, 69(7), 1046–1056. https://doi.org/10.4088/jcp.v69n0702
Nielsen, J., Skadhede, S., & Correll, C. U. (2010). Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology, 35(9), 1997–2004. https://doi.org/10.1038/npp.2010.78
Olfson, M., Gerhard, T., Huang, C., Crystal, S., & Stroup, T. S. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(12), 1172–1181. https://doi.org/10.1001/jamapsychiatry.2015.1737
Onyeka, I. N., Høegh, M. C., Eien, E. M. N., Nwaru, B. I., & Melle, I. (2019). Comorbidity of physical disorders among patients with severe mental illness with and without substance use disorders: A systematic review and meta-analysis. Journal of Dual Diagnosis, 15(3), 192–206. https://doi.org/10.1080/15504263.2019.1619007
Panocka, I., Pompei, P., & Massi, M. (1993). Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist. Brain Research Bulletin, 31(5), 595–599. https://doi.org/10.1016/0361-9230(93)90128-x
Perry, B. I., McIntosh, G., Weich, S., Singh, S., & Rees, K. (2016). The association between first-episode psychosis and abnormal glycaemic control: Systematic review and meta-analysis. The Lancet Psychiatry, 3(11), 1049–1058. https://doi.org/10.1016/S2215-0366(16)30262-0
Pillinger, T., Beck, K., Gobjila, C., Donocik, J. G., Jauhar, S., & Howes, O. D. (2017). Impaired glucose homeostasis in first-episode schizophrenia: A systematic review and meta-analysis. JAMA Psychiatry, 74(3), 261–269. https://doi.org/10.1001/jamapsychiatry.2016.3803
Poudyal, R., & Lohani, S. (2019). Clozapine associated pulmonary embolism: Systematic review. Journal of Community Hospital Internal Medicine Perspectives, 9(4), 300–304. https://doi.org/10.1080/20009666.2019.1627848
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. The New England Journal of Medicine, 360(3), 225–235. https://doi.org/10.1056/NEJMoa0806994
Ricciardi, L., Pringsheim, T., Barnes, T. R. E., Martino, D., Gardner, D., Remington, G., Addington, D., Morgante, F., Poole, N., Carson, A., & Edwards, M. (2019). Treatment recommendations for tardive dyskinesia. The Canadian Journal of Psychiatry, 64(6), 388–399. https://doi.org/10.1177/0706743719828968
Rotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020). Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. European Neuropsychopharmacology, 32, 56–65. https://doi.org/10.1016/j.euroneuro.2019.12.118
Saha, S., Chant, D., & McGrath, J. (2007). A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Archives of General Psychiatry, 64(10), 1123–1131. https://doi.org/10.1001/archpsyc.64.10.1123
SAS Institute. (2019). The Logistic Procedure. Retrieved from https://documentation.sas.com/doc/en/pgmsascdc/9.4_3.4/statug/statug_logistic_syntax22.htm#statug.logistic.logisticridging
Sinha, A., Shariq, A., Said, K., Sharma, A., Jeffrey Newport, D., & Salloum, I. M. (2018). Medical comorbidities in bipolar disorder. Current Psychiatry Reports, 20(5), 36. https://doi.org/10.1007/s11920-018-0897-8
Slim, M., Medina-Caliz, I., Gonzalez-Jimenez, A., Cabello, M. R., Mayoral-Cleries, F., Lucena, M. I., & Andrade, R. J. (2016). Hepatic safety of atypical antipsychotics: Current evidence and future directions. Drug Safety, 39(10), 925–943. https://doi.org/10.1007/s40264-016-0436-7
Smelson, D. A., Losonczy, M. F., Davis, C. W., Kaune, M., Williams, J., & Ziedonis, D. (2002). Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. The Canadian Journal of Psychiatry, 47(7), 671–675. https://doi.org/10.1177/070674370204700710
Sokal, J., Messias, E., Dickerson, F. B., Kreyenbuhl, J., Brown, C. H., Goldberg, R. W., & Dixon, L. B. (2004). Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. The Journal of Nervous and Mental Disease, 192(6), 421–427. https://doi.org/10.1097/01.nmd.0000130135.78017.96
Stegmayer, K., Walther, S., & van Harten, P. (2018). Tardive dyskinesia associated with atypical antipsychotics: Prevalence mechanisms and management strategies. CNS Drugs, 32(2), 135–147. https://doi.org/10.1007/s40263-018-0494-8
Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Nussbaum, A. M., Lieberman, J. A., Schizophrenia Trials Network. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). The American Journal of Psychiatry, 168(9), 947–956. https://doi.org/10.1176/appi.ajp.2011.10111609
Stubbs, B., Vancampfort, D., De Hert, M., & Mitchell, A. J. (2015). The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: A systematic review and comparative meta-analysis. Acta Psychiatrica Scandinavica, 132(2), 144–157. https://doi.org/10.1111/acps.12439
Svalheim, S., Luef, G., Rauchenzauner, M., Morkrid, L., Gjerstad, L., & Tauboll, E. (2010). Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurologica Scandinavica, 122(Suppl 190), 30–33. https://doi.org/10.1111/j.1600-0404.2010.01372.x
Tomasik, J., Lago, S. G., Vazquez-Bourgon, J., Papiol, S., Suarez-Pinilla, P., Crespo-Facorro, B., & Bahn, S. (2019). Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment. JAMA Psychiatry, 76(8), 864–867. https://doi.org/10.1001/jamapsychiatry.2019.0304
Truyers, C., Buntinx, F., De Lepeleire, J., De Hert, M., Van Winkel, R., Aertgeerts, B., Bartholomeeusen, S., & Lesaffre, E. (2011). Incident somatic comorbidity after psychosis: Results from a retrospective cohort study based on Flemish general practice data. BMC Family Practice, 12, 132. https://doi.org/10.1186/1471-2296-12-132
van Veggel, M., Olofinjana, O., Davies, G., & Taylor, D. (2013). Clozapine and gastro-oesophageal reflux disease (GORD) - an investigation of temporal association. Acta Psychiatrica Scandinavica, 127(1), 69–77. https://doi.org/10.1111/j.1600-0447.2012.01920.x
Wang, M. T., Tsai, C. L., Lin, C. W., Yeh, C. B., Wang, Y. H., & Lin, H. L. (2017). Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry, 74(3), 252–260. https://doi.org/10.1001/jamapsychiatry.2016.3793
Ward, M., & Druss, B. (2015). The epidemiology of diabetes in psychotic disorders. The Lancet Psychiatry, 2(5), 431–451. https://doi.org/10.1016/S2215-0366(15)00007-3
Weber, N. S., Cowan, D. N., Millikan, A. M., & Niebuhr, D. W. (2009). Psychiatric and general medical conditions comorbid with schizophrenia in the National hospital discharge survey. Psychiatric Services, 60(8), 1059–1067. https://doi.org/10.1176/appi.ps.60.8.1059
Weiden, P. J. (2007). EPS profiles: The atypical antipsychotics are not all the same. Journal of Psychiatric Practice, 13(1), 13–24. https://doi.org/10.1097/00131746-200701000-00003
Weiden, P. J., Daniel, D. G., Simpson, G., & Romano, S. J. (2003). Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. Journal of Clinical Psychopharmacology, 23(6), 595–600. https://doi.org/10.1097/01.jcp.0000095347.32154.08
Wu, C. S., Wang, S. C., Yeh, I. J., & Liu, S. K. (2016). Comparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disorders. The Journal of Clinical Psychiatry, 77(5), e573-579. https://doi.org/10.4088/JCP.15m09898
Acknowledgements
The authors would like to acknowledge Jessica Lee and Damianne Ra'Shadd, data analysts in the Department of Behavioral Health at Grady Memorial Hospital.
Funding
This work is supported by funding from NIMH K23 MH114037 (DRG).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial conflict of interest to report.
Ethical Approval
This study was approved by the Emory University IRB and was considered non-human subjects research, thus meeting exemption criteria for the Grady Memorial Hospital Research Oversight Committee.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bennett, C.W., Gensler, L. & Goldsmith, D.R. Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic. Community Ment Health J 59, 641–653 (2023). https://doi.org/10.1007/s10597-022-01045-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10597-022-01045-2